75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss 2 link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Changes in Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Consolidated Statements of Cash Flows (Cal2) link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - Condensed Consolidated Statements of Changes in Stockholders Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75080 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of the business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Collaboration agreement with AbbVie link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance sheet components link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Employee benefit plan link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Strategic transactions and agreements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Common stock link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Share-based compensation link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Segment information link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Collaboration agreement with AbbVie (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Balance sheet components (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Strategic transactions and agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Common stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Share-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Segment information (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Nature of the business (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Summary of significant accounting policies - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Fair value measurement - Financial assets measured at fair value (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair value measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Collaboration agreement with AbbVie - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance sheet components - Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Employee benefit plan (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Strategic transactions and agreements - Ayala Pharmaceuticals - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Strategic transactions and agreements - Zentalis Pharmaceuticals (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Strategic transactions and agreements - Bristol-Myers Squibb (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Strategic transactions and agreements - Other asset acquisitions and license agreements (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Leases - Lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Leases - Additional lease related information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Leases - Cash flow information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Leases - Lease maturity (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Leases - Lease maturity (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Common stock - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Common stock - Stock for issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Share-based compensation - Plans (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Share-based compensation - Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Share-based compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Share-based compensation - Costs (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 999009 - Disclosure - Anchoring link:presentationLink link:calculationLink link:definitionLink Other Research and Development Expense Other product candidates Other product candidates Segments [Domain] Entity Incorporation, State or Country Code Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Represents the upfront payment in cash under license agreement. License Agreement, Upfront Payment in Cash Upfront consideration paid in cash Increase (Decrease) in Accounts Payable Accounts payable Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosures of non-cash investing and financing activities: Plan Name [Axis] Entity Current Reporting Status Proceeds from Warrant Exercises Proceeds from exercise of common stock warrants Represents the information pertaining to Bristol Myers Squibb. Bristol Myers Squibb [Member] BMS License Agreement Bristol myers squibb Operating Expenses [Abstract] Operating expenses: Less: The amount of license fee payable on commercial milestones. Collaborative Arrangements, Commercial Milestone Payments Payable Commercial milestone payments License agreement with Zentalis Pharmaceuticals, Inc Represents the member information pertaining to license agreement with Zentalis Pharmaceuticals, Inc. License Agreement with Zentalis Pharmaceuticals, Inc. [Member] Fair Value, Inputs, Level 2 [Member] Level 2 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise price Common Stock, Shares Authorized Common stock, shares authorized (in shares) Document Fiscal Period Focus Collaboration agreement with AbbVie Entity Shell Company Segment Reporting, Policy [Policy Text Block] Segment and geographic information Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Non-restricted cash and cash equivalents Amount of transaction costs incurred in transactions under the license agreement. License Agreement, Transaction Cost Transaction cost Common Stock, Shares, Issued Common stock, shares issued (in shares) Asset Class [Domain] Statement [Table] The amount of sales based milestone receivable upon achievement of target. Collaborative Arrangement, Sales Based Milestone Sales based milestone based on achievement Restricted Cash, Noncurrent Restricted cash Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Robert Lechleider [Member] Robert Lechleider. Robert Lechleider Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Common stock Statement [Line Items] Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired Common stock warrants Entity Filer Category Represents information pertaining to single reportable segment. Single Reportable Segment [Member] Single reportable segment Liabilities and Equity Total liabilities and stockholders' equity Balance sheet components Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable Long-Lived Tangible Asset [Axis] Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Shares Issued, Price Per Share Represents the information pertaining to office and laboratory space in Exton. Office and Laboratory Space in Exton, [Member] Office and Laboratory Space in Exton Stock options outstanding Impairment for Marketable Securities Impairment for Marketable Securities Impairment for marketable securities Restricted Cash Restricted cash Employee benefit plan Defined Contribution Plan [Text Block] Employee benefit plan Significant Accounting Policies [Text Block] Summary of significant accounting policies Vesting [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, Granted Earnings Per Share, Basic Net loss per share, basic Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Ending balance Options, Beginning balance Stock options issued and outstanding under the Plans Liabilities, Current Total current liabilities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Represents the member information pertaining to follow-on public offering. Follow-On Public Offering [Member] Public offering Entity Small Business Number of shares of equity interests issued or issuable to acquire assets. Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number of Shares Issued Number of shares issued Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Forfeited ABHMC II LLC [Member] ABHMC II LLC. ABHMC II LLC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value, exercised Share-based Payment Arrangement [Text Block] Share-based compensation Nature of the business The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other current liabilities. Increase (Decrease) in Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Leases [Abstract] Leases The amount of cash inflow from non-refundable upfront payment. Collaboration Arrangement, Proceeds from Non Refundable Upfront Payment Upfront payment Project [Domain] Lessee, Lease, Description [Line Items] Amendment Flag Amount of lessee's obligation to pay to lessor for lease improvements under operating lease. Lessee, Operating Lease Liability, Lease Improvement Allowance Less: Tenant improvement allowance not yet received Earnings Per Share, Policy [Policy Text Block] Net loss per share Liabilities and Equity [Abstract] Liabilities and stockholders' equity Entity Address, Postal Zip Code Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Increase (Decrease) in Operating Lease Liability Operating lease liabilities Common stock [Table] Common stock. Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Lessee, Operating Lease, Liability, to be Paid, Year Three 2029 Debt Securities, Available-for-Sale [Line Items] Maximum commission percentage on the aggregate gross proceeds that is agreed to be paid under the stock sale agreement. Maximum Percentage Of Commission Payable Percentage of commission Entity Address, Address Line One Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions used in the Black-Scholes option-pricing Fair Value Hierarchy and NAV [Axis] Earnings Per Share [Abstract] Per share information: Tabular disclosure of the components of accrued expenses and other current liabilities. Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Represents information pertaining to IM-3050, fibroblast activation protein. IM-3050, Fibroblast Activation Protein [Member] IM-3050 Operating right-of-use asset Operating right-of-use assets Operating lease right-of-use assets Payments to Acquire Debt Securities, Available-for-Sale Purchases of marketable securities Kinney Horn Kinney Horn [Member] Kinney Horn. Total number of options available to extend the lease term. Lessee, Operating Lease, Number Of Options To Extend Number of options available to extend the lease term. The amount of milestone consideration on product sales accrued and payable as certain milestones were achieved. Collaborative And License Agreements, Milestones payments On Product Sales, Accrued And Payable, As Milestones Achieved Accrued expenses and other current liabilities Document Type Type of Arrangement [Axis] Type of Arrangement [Domain] Entity Central Index Key Tenant improvement allowance Payments for (Proceeds from) Tenant Allowance Represents information pertaining to open market sale agreement. Open Market Sale (ATM Agreement) ATM Open Market Sale Asset Acquisition [Table] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash and cash equivalents and restricted cash 2031 and thereafter Lessee Operating Lease Liability Payments Due Year Five And After Year Five Lessee operating lease liability payments due year five and after year five. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities Common Stock, Par or Stated Value Per Share Common stock par value (in dollars per share) Share-based Payment Arrangement, Tranche One [Member] One-year anniversary Operating Lease, Right-of-Use Asset, Amortization Expense Amortization of right-of-use asset Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term Asset Acquisition, Contingent Consideration, Liability Payment to be made in cash Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Debt Securities, Available-for-Sale Fair Value Debt Securities, Available-for-Sale, Total Marketable securities Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options (in shares) Options, Exercised The amount of maximum aggregate payment payable under the license agreement. License Agreement, Maximum Aggregate Payment Payable Maximum amount payable Current Fiscal Year End Date Document Quarterly Report Entity Address State Or Province Asset Acquisition [Domain] Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gain Common Stock, Capital Shares Reserved for Future Issuance Shares available for future issuance Total reserved common stock Tabular disclosure of supplemental cash flow related information. Schedule of Supplemental Cash Flow Related Information [Table Text Block] Supplemental cash flow information Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Balance sheet components Collaborative Arrangement Disclosure [Text Block] Collaboration agreement with AbbVie Represents information pertaining to other asset purchase and license agreements. Other Asset Purchase And License Agreements [Member] Other asset acquisitions and license agreements Offering costs in accounts payable and accrued expenses and other current liabilities Offering Cost Included In Accounts Payable Accrued Expenses And Other Current Liabilities Offering cost included in accounts payable accrued expenses and other current liabilities. Other Segment Expenses Other segment expenses. Other segment expenses Other segment expenses Other Assets, Noncurrent Other long-term assets Debt Securities, Available-for-Sale, Current Marketable securities Antidilutive Securities [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options, Expired Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Percentage of vesting Amount of additional tenant lease improvements. Additional Tenant Lease Improvements Additional tenant improvement allowance AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Cash [Member] Cash equivalents Increase (Decrease) in Stockholders' Equity [Roll Forward] Represents the information pertaining to public offering. Public Offering [Member] Public offering Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at June 30, 2026 and December 31, 2025 The cash inflow associated with the amount received from entity's raising of capital via public offering. Proceeds From Public Offering Proceeds from public offerings Minimum Minimum [Member] Assets, Current [Abstract] Current assets: Increase in number of shares available for future issuance under the share-based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Increase in Number of Shares Available for Future Issuance Increase in shares available for future issuance Segment information Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value on a recurring basis Liabilities, Current [Abstract] Current liabilities: Balance (in shares) Shares, Outstanding Balance (in shares) This member stands for office and laboratory space . Office and laboratory space Office and laboratory space Lessee, Operating Lease, Renewal Term Additional lease term Maximum price at which the company would offer to sell its shares under the sales agreement. Common Stock, Maximum Offering Price Of Shares Offering price of shares Commitments and Contingencies Commitments and contingencies (Note 7) The cash outflow for cost incurred directly with the issuance of an equity security. Payment of Offering Costs Payment of offering costs General and administrative General and administrative Represents information pertaining to IM-1021, a receptor tyrosine kinase-like orphan receptor 1, or ROR1. IM-1021, ROR 1 [Member] IM-1021 Operating Lease, Liability Total operating lease liabilities Present value of operating lease liabilities The gross cash inflow from the additional capital contribution to the entity, before deducting issuance costs. Gross Proceeds from Issuance of Common Stock Gross proceeds from issuance of common shares The amount of additional platform access payments receivable. Additional Platform Access Payment Receivable Additional platform access payments Lessee, Lease, Description [Table] Interest Income (Expense), Net Interest income Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Represents information pertaining to 2024 inducement plan. Inducement Plan 2024 [Member] 2024 Inducement Plan Weighted Average Number of Shares Outstanding, Basic Weighted-average shares outstanding, basic The amount of in process research and development expense incurred during the year. In Process Research and Development Expense In-process research and development Charge for purchase of in-process research and development assets In-process research and development Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Intrinsic value, exercisable Tabular disclosure of operating lease additional information. Schedule of Lessee, Operating Lease, Additional Information [Table Text Block] Schedule of other information related to the operating lease Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Segments [Axis] Long-Lived Tangible Asset [Domain] Asset Acquisition, Consideration Transferred, Transaction Cost Transaction costs APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Preferred stock par value (in dollars per share) Preferred stock par value (in dollars per share) Basis of Accounting, Policy [Policy Text Block] Basis of presentation Condensed Consolidated Statements of Changes in Stockholders' Equity Share-based Payment Arrangement, Tranche Two [Member] Over next 36 months Use of Estimates, Policy [Policy Text Block] Use of estimates Leasehold Improvements Leasehold Improvements [Member] Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair value measurement Project [Axis] Number of shares Number of shares Term of anniversary for first commercial sale. Term of Anniversary for First Commercial Sale Anniversary of first commercial sale (in years) Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Represents information pertaining to employee stock purchase plan 2020. 2020 Employee Stock Purchase Plan ESPP Employee Stock Purchase Plan Plan Name [Domain] Value of common stock warrants exercised. Stock Issued During Period, Value, Stock Warrants Exercised Exercise of common stock warrants Contractual maturity term of debt securities available for sale. Debt Securities, Available-for-Sale, Contractual Maturity Term Contractual maturity term Contractual maturities Entity Address, City or Town Number of Reportable Segments Number of reportable segments Represents the information pertaining to Dr. Clay Siegall, President and CEO of Morphimmune. President and CEO of Morphimmune [Member] Dr. Clay Siegall Security Exchange Name Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total Unrealized loss on marketable securities Antidilutive Securities, Name [Domain] Common stock Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents and restricted cash at end of period Cash and cash equivalents and restricted cash at beginning of period Total cash, cash equivalents, and restricted cash Statistical Measurement [Domain] Assets, Current Total current assets Share-based Payment Arrangement, Expense Total share-based compensation expense Document Period End Date Title of Individual [Axis] Fair Value Hierarchy and NAV [Domain] Defined Contribution Plan, Cost Defined contribution Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options, Exercisable Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Condensed Consolidated Balance Sheets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Vesting [Axis] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Reconciliation of cash and cash equivalents and restricted cash: Liabilities Total liabilities Common Stock [Line Items] Common stock. Earnings Per Share, Diluted, Other Disclosures [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year Two 2028 Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares outstanding, diluted Entity File Number OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on marketable securities Unrealized gain (loss) on marketable securities Document and Entity Information [Abstract] Amount of research and development expense directly attributable to the acquired in-process research and development program. Direct Expense Of Acquired In Process Program Research And Development Program Direct research and development expenses Direct research and development expenses Represents the information pertaining to office and laboratory space in Bothwell. Office and Laboratory Space in Bothwell, [Member] Office and Laboratory Space in Bothwell Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets US Treasury Securities [Member] U.S. Treasury securities Number of Operating Segments Number of operating segments Sale of Stock [Domain] Segment Reporting Disclosure [Text Block] Segment information General and Administrative Expense General and administrative General and administrative Represents the member information pertaining to Zentalis Purchase Agreement. Zentalis Purchase Agreement [Member] Zentalis Asset Purchase Agreement Asset Acquisition, Contingent Consideration, Liability, Current Development milestone amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting standards not yet adopted Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of future minimum lease payments under operating lease Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Contract with Customer, Liability, Current Deferred revenue, current Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Development milestones Accrued Development Milestones Accrued development milestones. Represents the information pertaining to Collaboration Agreement with AbbVie. Collaboration agreement with AbbVie. Collaboration agreement with AbbVie Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) Operating Lease, Liability, Current Operating lease liabilities, current portion Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Depreciation, Depletion and Amortization Depreciation and amortization Represents information pertaining to Morphimmune Inc. Morphimmune Inc Morphimmune Revenue, Remaining Performance Obligation, Amount Performance obligation Additional area of real estate property. Additional Area Of Real Estate Property Additional Area Document Transition Report Number of common stock warrants exercised during the period. Stock Issued During Period, Shares, Stock Warrants Exercised Exercise of common stock warrants (in shares) Operating Expenses Total operating expenses Total operating expenses Research and Development Expense Research and development Lessee, Operating Leases [Text Block] Leases Condensed Consolidated Statements of Cash Flows Stock Issued During Period, Value, New Issues Issuance of common stock Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of option activity Equity [Text Block] Common stock IM-1617 Potential First-in-Class ADC [Member] IM-1617 Potential First-in-Class ADC. IM-1617 Net loss Net loss Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value, outstanding Represents information pertaining to equity incentive 2020 plan. 2020 Plan Represents the discount percentage related to unregistered share restrictions. Percentage Of Discount Related To Unregistered Share Restrictions Percentage of discount related to unregistered share restrictions to be deducted from the share price Operating Lease, Cost Operating lease cost Operating Lease, Payments Cash paid for operating lease liabilities Assets [Abstract] Assets Assets acquired: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Document Fiscal Year Focus Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Accounts Payable, Current Accounts payable Represents the member information pertaining to Ayala Purchase Agreement. Ayala Purchase Agreement [Member] Ayala Asset Purchase Agreement Ayala Pharmaceuticals Research and development Research and development Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of change in deferred revenue Deferred Revenue Deferred Revenue, Total Deferred revenue Liabilities Assumed Net liabilities assumed from purchases of in-process research and development assets Proceeds from Stock Options Exercised Proceeds from exercise of stock options Fair value measurement Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Lessee, Operating Lease, Liability, to be Paid, Year One 2027 Net Income (Loss) Available to Common Stockholders, Basic Net loss Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Common stock issued Share-based compensation Amount of research and development expense not directly attributable to particular product candidate but for the devision as a whole. Indirect Research And Development Expense Indirect research and development Indirect research and development Sale of Stock [Axis] Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Title of 12(b) Security Schedule of Segment Reporting Information, by Segment [Table] Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Money Market Funds [Member] Money market funds Collaborative Arrangement and Arrangement Other than Collaborative [Table] The amount of stock issued in exchange for in process research and development under non-cash investing and financing activities. Stock Issued In Exchange For In Process Research And Development Issuance of common stock in exchange for in-process research and development assets Accrued Manufacturing Expenses Accrued manufacturing expenses. Manufacturing expenses Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2026 (represents remaining six months in 2026) Other direct research and development Other Direct Research and Development Other direct research and development. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending price Beginning price Fair Value, Recurring and Nonrecurring [Table] The entire disclosure of information relating to asset acquisitions and license agreements. Asset Acquisitions And License Agreements Disclosure [Text Block] Strategic transactions and agreements Additional Paid-in Capital Additional Paid-in Capital Measurement Frequency [Domain] Income Statement Location [Axis] Isaac Barchas Member Isaac Barchas Member Isaac Barchas Trading Symbol Employee-related Liabilities, Current Compensation and related benefits Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Recurring Recurring Entity Ex Transition Period Lessee, Operating Lease, Liability, to be Paid Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Equity Components [Axis] Equity Component [Domain] Asset Class [Axis] Maximum Maximum Amount of tenant lease improvements granted during the period. Tenant Lease Improvements Tenant improvement allowance Statistical Measurement [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Common Stock, Value, Issued Common stock, $0.0001 par value; 300,000,000 shares authorized at June 30, 2026 and December 31, 2025; 113,399,202 and 113,133,199 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Represents information pertaining to MorphImmune Pla. MorphImmune Plan Consolidation, Policy [Policy Text Block] Principles of consolidation Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition. Asset acquisition, Share Price Share Price Entity Registrant Name Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Loss Payments to Acquire in Process Research and Development Purchases of in-process research and development assets Additional Paid in Capital Additional paid-in capital Accrued Clinical Development Expenses Accrued clinical development expenses. Clinical development expenses Measurement Frequency [Axis] Payments to Acquire Productive Assets Upfront consideration paid to Ayala Securities (Assets) [Member] Marketable securities (U.S. treasury securities) The value of shares remaining available for future offerings. Sale of Stock, Shares Available for Future Issuance, Value Value of shares available for future issuance Proceeds from Issuance of Common Stock Proceeds from issuance of common stock under ATM Proceeds from issuance of common stock Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Common stock Entity Common Stock, Shares Outstanding Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of credit risk Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) income Accumulated other comprehensive loss Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Awards granted Assets Total assets Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Exercisable Condensed Consolidated Statements of Operations and Comprehensive Loss Issuance of common stock (in shares) Sale of common stock in connection with IPO (shares) Shares issued The amount of product development and commercial sale milestone receivable per target. Collaborative Arrangements Product Development and Commercial Sale Milestone Receivable per Target Development and commercial sale milestone receivable per target Earnings Per Share, Diluted Net loss per share, diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment financial information Title of Individual [Domain] Asset Acquisition [Axis] City Area Code No definition available. Strategic transactions and agreements Variable lease cost Variable Lease, Cost The estimated period of research and development, during which the deferred revenue will be recognized. Research and Development Estimated Period, Recognition of Deferred Revenue Estimated research and development period Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (in years) Segment Reporting Information [Line Items] Impairment for Accrued Interest Receivable Impairment for accrued interest receivable. Impairment for accrued interest receivable Property, Plant and Equipment, Net Property and equipment, net Operating Income (Loss) Loss from operations Purchases Of In process Research And Development Assets Including Payments Owed Upon Achievement Of Development Milestones In Accounts Payable And Accrued Expenses Purchases of in process research and development assets including payments owed upon achievement of development milestones in accounts payable and accrued expenses. Purchases of in-process research and development assets, including payments owed upon achievement of development milestones, in accounts payable and accrued expenses Accumulated deficit Accumulated Deficit Share-based Payment Arrangement, Noncash Expense Share-based compensation expense Asset Acquisition, Consideration Transferred Consideration paid Consideration paid Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Fair Value, Inputs, Level 1 [Member] Level 1 Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Asset Acquisition [Table Text Block] Schedule of fair values of the assets acquired and liabilities Remeasurement of operating right-of-use asset and lease liability due to lease modification Remeasurement Of Operating Lease Right Of Use Asset And Lease Liability Due To Lease Remeasurement of operating lease right of use asset and lease liability due to lease. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of dilutive securities have been excluded from the computation of diluted net loss per share Entity Interactive Data Current Deferral of revenue Increase (Decrease) in Contract with Customer, Liability Deferred revenue Income Statement Location [Domain] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Asset Acquisition [Line Items] Asset acquisitions Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discounts on marketable securities Represents information pertaining to Varegacestar product candidate. Varegacestar Product Candidate [Member] Varegacestat Represents information pertaining to equity incentive plan 2020 and Morphimmune plan. Equity Incentive Plan 2020 and Morphimmune Plan [Member] 2020 Equity Incentive Plan Entity Tax Identification Number Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Share Price Share price per share Arsenal Bridge Venture II B LLC [Member] Arsenal Bridge Venture II B LLC. Arsenal Bridge Venture II-B LLC Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Maturities of marketable securities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of the business Local Phone Number Other Liabilities, Current Other Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation cost Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Net of issuance costs Summary of significant accounting policies Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Recognition of revenue 2029 2030 Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for grant Remaining shares available for issuance under the Plans and ESPP Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Recognition period The tabular disclosure of reserved shares of common stock for issuance, on an as-converted basis. Summary Of Reserved Shares Of Common Stock For Issuance [Table Text Block] Summary of reserved shares of common stock for issuance, on an as-converted basis Entity Emerging Growth Company Area of Land Area